Christi Shaw - 14 Feb 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Director
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Issuer symbol
KYTX
Transactions as of
14 Feb 2025
Net transactions value
$0
Form type
4
Filing time
19 Feb 2025, 17:55:53 UTC
Previous filing
18 Sep 2024
Next filing
02 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +38,679 $0.000000 38,679 14 Feb 2025 Common Stock 38,679 $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option shall be fully vested and exercisable on October 30, 2025, subject to the Reporting Person's continuous service to the Issuer as an advisor on and through the vesting date, inclusive.